BURLINGAME, Calif.–(BUSINESS WIRE)– Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, will present positive topline data from the landmark PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT) in a late-breaking poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders on September 25, 2019, in Nice, France. Cala Therapy, now marketed as Cala TrioTM, is available by prescription in the United States. This wrist-worn neuromodulation therapy is the only non-invasive individualized therapy for essential tremor (ET). For a multimedia release with additional creative assets, click here.
Cala Health Announces Positive Topline Data from Landmark PROSPECT Study for Essential Tremor
Posted on February 7, 2020